Anti-CA19-9/Sialyl Lewisa (GI Tumor Marker) Monoclonal Antibody(Clone: SPM588)(Discontinued)
|Amount :||100 µg|
|Isotype :||Mouse IgM, kappa|
|Content :||200 µg/ml of Ab Purified from Bioreactor Concentrate. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.|
|Storage condition :||Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous.|
|Alternative Name :||CA19.9, Ovarian tumor antigen, Pancreatic tumor antigen, Sialyl Lewis a|
|Immunogen Information :||Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B- patient (0Le).|
CA19-9, a carbohydrate epitope expressed on a high MW (400kDa) mucin glycoprotein, is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings. This MAb is excellent for staining of formalin-fixed, paraffin-embedded tissues.
Flow Cytometry (0.5-1µg/million cells); Immunofluorescence (0.5-1µg/ml); Immunohistochemistry (Formalin-fixed) (0.5-1.0µg/ml for 30 minutes at RT)(No special pretreatment is required for the immunohistochemical staining of formalin-fixed, paraffin-embedded tissues.)Optimal dilution for a specific application should be determined.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.